I'm cautious with this trade. I don't usually get into positions with a risk/reward smaller than 3.
- Target Entry: $25.65
- Target Stop Loss: $25.05
- Target Exit: $27.19
- Risk / Reward Ratio: 2.57
About me
- Note that I tend to adjust stop losses in order to secure profits early and preserve capital. This means that the target price is going to be achieved...
Hi guys, hope you are all well. Today we are looking at Exelixis, an oncology-focused biotechnology company that focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The market cap of the firm is roughly $7 billion. What drew me to looking into this company was its cash and cash equivalents value, a...
1st published idea for my new process which begins with the stock screener. I am trying to identify stocks that have bottomed out or at least hit a lower resistance that begin to have upwards momentum in the RSI coupled with an EMA crossover event.
Initial Filters:
>2B Market Cap to filter small companies
Debt to Equity Ratio (MRQ) < 0.5 to mitigate some...
The company pre announced improved earnings and guidance over the weekend.
stock was in a channel ( bull-flag)
potential entry above POC @ $25
target $27.25
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the...
I feel like this could turn into another false down-break, but it is getting close to a breakout.
There is a good amount of volume that has been leveling out nicely, and I would expect a breakout later in the week, but this might another opportunity. However, buyers have had a little more control over this, and it's already broken through 1 of the major supports.
In this article I will tell you about another metrics, which can be usefull at analysis of the company. Based on GuruFocus metrics.
Another metrics from Financial Strenghs metrics:
Piotrowski F-score — used for understanding of the financial strengh of the company. Scores from 0 to 9. 1 score means, that company have one of the characteristics (positive...
Hey people, EXELIXIS is in a bullish continuation with a large buying volume. And on the TIMEFRAME 1 Min a refusal of the sellers accompanied by a bearish volume. It goes to its next low point then starts rising again, Great potential to come to the highest before.
Please LIKE & FOLLOW, thank you!
It seems like the stock Exelixis has lower highs and higher lows, makes a perfect pennant. It is highly possible that Exelixis will break out above the upper line of the triangle and so it will have the potential to go to 27.81
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
NASDAQ
